If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00757055
Recruitment Status : Withdrawn (Difficulty recruit pts with PSHF HR > 70 & high BNP.)
First Posted : September 22, 2008
Last Update Posted : November 25, 2014
Information provided by (Responsible Party):
Dermot McCaffrey, St Vincent's University Hospital, Ireland

September 19, 2008
September 22, 2008
November 25, 2014
December 2012
November 2013   (Final data collection date for primary outcome measure)
Improvement in echocardiographic indices of diastolic dysfunction [ Time Frame: 12 weeks ]
Same as current
Complete list of historical versions of study NCT00757055 on Archive Site
  • Improvement in 6 minute walk test [ Time Frame: 12 weeks ]
  • Patient global assessment [ Time Frame: 12 weeks ]
Same as current
Not Provided
Not Provided
If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure
If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure

The purpose of this study is to investigate whether the medicine ivabradine, a novel drug which slows the heart rate has a favourable effect on patients with diastolic heart failure.

Ivabradine is a specific heart rate-lowering agent. It has a licence for treating patients with angina who are intolerant of agents such as beta blockers or whose angina is not adequately controlled. It has been shown to prolong exercise tolerance in these patients and to reduce the frequency of chest pain. Its mechanism of action is felt to be purely due to reducing heart rate, by as much as 10 beats per minute at rest, as well as by reducing the heart rate response to exercise.

Patients with diastolic heart failure often complain of breathlessness on exertion which relates to the stiffness or lack of compliance of their heart i.e. the heart fails to relax rapidly enough to allow it to fill with blood between each heart beat. This may result in high pressure in the heart chamber which backs up in to the lungs and may be experienced as breathlessness. There is little evidence that any specific therapy benefits patients with this type of heart failure besides treating coexisting problems such as high blood pressure or angina. By slowing the heart rate down with ivabradine, the heart would have a longer time to fill during exercise which would make it more effective. This slowing of the heart rate may therefore relieve the breathlessness experienced on activity such as walking to the shops or up a flight of stairs etc.


Almost half of all patients with heart failure (HF) have preserved systolic function (PSHF) or heart failure with normal ejection fraction (HFNEF). Some of these have valvular abnormalities such as severe mitral or aortic regurgitation, severe anaemia, thyrotoxicosis or rarer tropical causes for heart failure. However, the majority of those with PSHF often have echocardiographic evidence of impaired diastolic function i.e. impaired relaxation and increased stiffness. This diastolic dysfunction may be related to age, hypertension or ischaemia. There is little evidence for any effective therapy in this large HF population despite randomised trials comparing placebo to ACE inhibitors i.e. perindopril in PEP-HF or angiotensin receptor blockers i.e. candesartan in the CHARM Preserved trial. There are also ongoing studies of aldosterone antagonists in diastolic heart failure i.e. eplerenone vs placebo in TOPCAT which continues to recruit.

In the absence of a strong evidence base, many physicians treat these patients with drugs that slow the heart rate, namely the calcium channel blocker verapamil and beta blockers. This has the effect of prolonging diastole or filling time and theoretically improving stroke volume thus reducing left ventricular end diastolic pressures (LVEDP) with resultant drop in wall stress and therefore less stimulus for myocardial fibrosis which exacerbates diastolic dysfunction by impeding compliance.


An alternative mechanism for slowing the heart rate is with ivabradine, a novel If channel blocker which acts purely on the sino atrial node with a mean heart rate lowering of 10 bpm in angina patients. This may result in improved diastolic filling which could be demonstrate by echocardiography, lower pulmonary capillary wedge pressures, which could be determined by measuring the E:E' ratio using tissue Doppler techniques, improving effort tolerance, estimated by assessing change in distance walked over 6 minutes and both a physician assessment using NYHA score as well as a patient Global Assessment and possibly better quality of life, determined by the Minnesota Living with Heart Failure Questionnaires.

Other theoretical improvements could be in the degree of stiffness or fibrosis due to reduced LV wall stress secondary to the longer filling time. This could be assessed using surrogates of wall strain such as brain natruretic peptide (BNP), wall stress as measured by strain rate imaging on echocardiography.

Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Diastolic Heart Failure
  • Drug: Ivabradine
    Ivabradine titrated to heart rate starting at 5 mg bd and increasing to maximum of 7.5 mg bd or reducing to 2.5 mg if heart rate < 60 bpm.
    Other Name: Procoralen is brand name for Ivabradine
  • Drug: Placebo
    No active treatment given
  • Active Comparator: 1
    Patients on ivabradine titrated to heart rate
    Intervention: Drug: Ivabradine
  • Placebo Comparator: 2
    No therapy given
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
January 2014
November 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

All patients must have a clinical diagnosis of diastolic heart failure as defined by all 3 of the following criteria:

  • Presence of clinical heart failure for greater than or equal to 3 months before the screening visit. At the time of enrollment they should be in NYHA functional class I-III heart failure
  • Left ventricular ejection fraction (LVEF) of greater than or equal to 50% (by echo or ventriculography) within 3 months of screening and LVEF still greater than or equal to 50% on day of enrollment
  • BNP (b-type natruretic peptide) greater than or equal to 200 pg/ml at time of heart failure diagnosis
  • Patients must be euvolaemic on clinical examination and have been clinically stable for at least 4 weeks with no medication changes
  • Systolic blood pressure less than or equal to 150 mmHg but > 85 mmHg and diastolic blood pressure less than or equal to 95 mmHg for 4 weeks prior to and at the time of enrollment
  • Able to walk at least 50 meters at time of enrollment

Exclusion Criteria:

  • Aged < 18 or > 85
  • Primary hemodynamically significant uncorrected valvular heart disease, obstructive or regurgitant
  • Any planned revascularisation i.e. CABG or stenting or performed within last 90 days
  • Any myocardial infarct within last 90 days
  • Significant chronic obstructive airways disease in the opinion of the investigator
  • Known infiltrative or hypertrophic obstructive cardiomyopathy or known pericardial constriction
  • Inability to sign informed consent
  • Atrial fibrillation
  • Heart transplant recipient
  • Currently implanted left ventricular assist device
  • Stroke in past 90 days
  • Gastrointestinal disorder that could interfere with study drug absorption
  • Known intolerance to ivabradine
  • Current participation (including prior 30 days) in any other therapeutic trial
  • Any condition that, in the opinion of the investigator, may prevent the participant from adhering to the trial protocol
Sexes Eligible for Study: All
18 Years to 85 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Dermot McCaffrey, St Vincent's University Hospital, Ireland
St Vincent's University Hospital, Ireland
Not Provided
Principal Investigator: Dermot J McCaffrey, MB MRCPI FRACP St Vincents University Hospital, Elm Park Dublin 4 Ireland
St Vincent's University Hospital, Ireland
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP